Sanjoinine A

Pharmacology & Research

Sanjoinine A — also called frangufoline — is a 14-membered (frangulanine-type) cyclopeptide alkaloid from the seed of sour jujube (Ziziphus jujuba var. spinosa, suan zao ren), the same seed that gives the saponins jujuboside A and jujuboside B. Its profile is thin and single-lab, anchored by a GABAergic sedative signal. The load-bearing discipline: the herb’s insomnia reputation belongs to the whole seed and the Suanzaoren decoction, in which jujuboside A and spinosin are the official quality markers — sanjoinine A is one minor contributor, not the driver — and there are no human trials of the isolate.

1. Sedative / hypnotic

The suan zao ren hook and most-cited finding. Sanjoinine A prolonged pentobarbital sleeping time and shortened onset in mice, with the effect linked to GABA-A chloride-channel activity ^{1Reference 1Ma Y et al. · 2007Sanjoinine A isolated from Zizyphi Spinosi Semen augments pentobarbital-induced sleeping behaviours through modification of GABAergic systemsView study →}.

Gap: a single rodent model with oral/i.p. dosing and no dose-response translation to the whole-seed decoction; human sedation in Ziziphus is attributed to the whole seed with jujuboside A and spinosin as co-actives, so sanjoinine A is a contributor, not the driver ^{1Reference 1Ma Y et al. · 2007Sanjoinine A isolated from Zizyphi Spinosi Semen augments pentobarbital-induced sleeping behaviours through modification of GABAergic systemsView study →}.

2. Anticonvulsant

Sanjoinine A protected against kainic-acid convulsions in mice (oral 4–8 mg/kg: ↑ survival, ↑ latency, ↓ seizure score, hippocampal neuroprotection, blocked seizure-form EEG) ^{2Reference 2Yoon SR et al. · 2009Sanjoinine A isolated from Semen Zizyphi Spinosi protects against kainic-acid-induced convulsionsView study →} and against NMDA-induced seizures ^{4Reference 4Ma Y et al. · 2008Protective effects of sanjoinine A against N-methyl-D-aspartate-induced seizureView study →}, with the mechanism proposed as increased intracellular chloride (GABA-A-consistent) plus blunted intracellular Ca²⁺ influx.

Gap: two chemically-induced acute seizure models from one lab group, with no chronic/epilepsy models, no independent replication and no human data ^{2,4Reference 2Yoon SR et al. · 2009Sanjoinine A isolated from Semen Zizyphi Spinosi protects against kainic-acid-induced convulsionsView study →Reference 4Ma Y et al. · 2008Protective effects of sanjoinine A against N-methyl-D-aspartate-induced seizureView study →}.

3. Anxiolytic

Sanjoinine A showed anxiolytic-like behaviour (elevated plus-maze), with “possible involvement of GABAergic transmission” ^{3Reference 3Han H et al. · 2009Anxiolytic-like effects of sanjoinine A isolated from Zizyphi Spinosi Semen: possible involvement of GABAergic transmissionView study →}.

Gap: a single preclinical study with hedged (“possible involvement”) mechanism and no human anxiety data ^{3Reference 3Han H et al. · 2009Anxiolytic-like effects of sanjoinine A isolated from Zizyphi Spinosi Semen: possible involvement of GABAergic transmissionView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
GABA-A / GABAergic transmission (Cl⁻ influx, subunit modulation)	potentiation → enhanced inhibitory tone (the repeatedly-supported mechanism)	sedative, anxiolytic, anticonvulsant
Pentobarbital co-administration	prolongs barbiturate sleeping time (in-vivo, mice)	sedative / hypnotic
Intracellular Ca²⁺ influx (KA / NMDA excitotoxicity)	inhibited; ↑ intracellular Cl⁻	anticonvulsant, hippocampal neuroprotection
Nitric oxide in LPS-activated macrophages	increased NO (single in-vitro assay)	immune signal — not anti-inflammatory
Calmodulin-dependent Ca²⁺-ATPase / phosphodiesterase (class-level)	inhibition	Ziziphus cyclopeptide class mechanism, not sanjoinine-A-specific

Honesty note: the one NO/iNOS study ^{6Reference 6Um S et al. · 2023Chromatographic determination of the absolute configuration in sanjoinine A that increases nitric-oxide productionView study →} shows sanjoinine A increasing nitric oxide in macrophages (a pro-NO/immunostimulatory, not anti-inflammatory, direction) and is primarily an absolute-configuration methods paper — so no anti-inflammatory claim is made here. The calmodulin-ATPase/PDE inhibition is a whole-genus cyclopeptide-class property, not shown for sanjoinine A specifically ^{7Reference 7Hwang KH et al. · 2001Inhibition of calmodulin-dependent calcium-ATPase and phosphodiesterase by various cyclopeptides and peptide alkaloids from the Zizyphus speciesView study →}.

Pharmacokinetics

There is minimal data, as expected for a cyclopeptide alkaloid. The one direct study is on frangufoline (= sanjoinine A): it is rapidly cleaved enzymatically in rodents at the enamide bond to a linear tripeptide metabolite, likely via a B-esterase-like enzyme (the reaction is inhibited by organophosphates/eserine, not by serum) ^{5Reference 5Suh DY et al. · 1997AnimalMetabolic cleavage of frangufoline in rodents: in-vitro and in-vivo studyView study →}. The implication is probable rapid first-pass/tissue metabolism and low intact-molecule persistence — yet in-vivo activity is still seen after oral dosing in mice (4–8 mg/kg). No formal oral bioavailability, Cmax, half-life or distribution data exist.

Clinical trials

There are no trials of isolated sanjoinine A. Human insomnia evidence belongs to the whole seed (suan zao ren) and the multi-herb Suanzaoren decoction ^{8Reference 8Zhou QH et al. · 2018Suanzaoren formulae for insomnia: updated clinical evidence and possible mechanismsView study →}, not to the isolated compound; the only single-herb Ziziphus trial is a small (n≈12) feasibility study of the seed.

Last checked: July 2026.

Toxicity & Safety

Sanjoinine A carries a low flag, reflecting limited data. It is a constituent of a food-and-medicine seed (suan zao ren) with a long ingestion history in decoction, and rodent efficacy studies at 4–8 mg/kg oral report no acute toxicity signal, with rapid metabolic cleavage arguing against accumulation. However, there is no dedicated isolate toxicology (no LD50, genotoxicity, repeat-dose or organ-toxicity data), and its CNS-depressant/GABAergic activity implies additive sedation risk with alcohol, benzodiazepines, barbiturates and other CNS depressants.

Pregnancy & lactation

Avoid (isolate). A GABAergic sedative with no reproductive-safety data, from a seed traditionally cautioned in pregnancy — there is no basis to consider the isolated compound safe. Whole-seed dietary/decoction exposure is a separate question outside this compound page.

Dosage

There is no established or recommended human dose. Cited figures are preclinical research doses only — sanjoinine A 4–8 mg/kg oral in mice (anticonvulsant), with comparable i.p./oral ranges in the sedative/anxiolytic studies. Human exposure occurs only via the whole seed — traditionally 9–18 g dry-fried suan zao ren in decoction — within which sanjoinine A is one minor cyclopeptide-alkaloid contributor alongside the marker constituents jujuboside A and spinosin.

References